Pediatrics – Allergy and Immunology
News Release – FDA Approves First Nasal Spray for Anaphylaxis Treatment: Neffy (Epinephrine Nasal Spray) – U.S. Food and Drug Administration
17 Aug, 2024 | 15:43h | UTCThe U.S. Food and Drug Administration (FDA) has approved Neffy, the first epinephrine nasal spray for the emergency treatment of anaphylaxis and other severe allergic reactions (Type I) in both adults and pediatric patients weighing at least 30 kilograms (approximately 66 pounds). This approval introduces a non-injectable option for the rapid administration of epinephrine, which is critical in managing life-threatening allergic reactions.
Key Points for Healthcare Providers:
– Alternative to Injection: Neffy provides a new option for patients who may delay or avoid epinephrine injections due to needle phobia. This could be particularly beneficial for children and others reluctant to use injectable epinephrine.
– Efficacy and Safety: Neffy’s approval is supported by studies comparing its pharmacokinetics and pharmacodynamics to traditional epinephrine injections. These studies showed comparable blood epinephrine levels and similar physiological effects, such as increased blood pressure and heart rate.
– Administration: Neffy is a single-dose nasal spray, administered into one nostril. If symptoms do not improve or worsen, a second dose may be administered in the same nostril. Patients should still seek emergency medical care to monitor the anaphylactic reaction.
– Warnings: Certain nasal conditions, such as nasal polyps or a history of nasal surgery, may impair Neffy’s absorption. In these cases, injectable epinephrine might be a more reliable option. The product also carries typical warnings for epinephrine use, particularly in patients with coexisting conditions.
– Side Effects: Common side effects include throat irritation, nasal discomfort, headaches, and jitteriness. Healthcare professionals should discuss these with patients to ensure informed use.
Clinical Implications:
Neffy may reduce barriers to the timely treatment of anaphylaxis, potentially improving outcomes by increasing the likelihood of rapid epinephrine administration. Healthcare providers should consider Neffy as an alternative for patients who are needle-averse or have difficulty using injectable epinephrine, while also ensuring patients understand the importance of prompt medical attention following its use.
Approval Background:
Neffy was granted Fast Track designation by the FDA, emphasizing the need for an alternative to injectable epinephrine. The approval was awarded to ARS Pharmaceuticals.
Source: FDA News Release: FDA Approves First Nasal Spray for Treatment of Anaphylaxis
RCT | Maternal egg intake in early neonatal period does not impact infant egg allergy risk
2 Aug, 2023 | 13:47h | UTCSee also: Visual Abstract
An ESPGHAN position paper on the diagnosis, management and prevention of cow’s milk allergy
31 Jul, 2023 | 14:28h | UTC
Adrenaline auto-injector prescription for patients at risk of anaphylaxis: BSACI guidance for primary care
6 Jun, 2023 | 14:28h | UTC
RCT | Peanut patch therapy is effective in desensitizing young children with allergies, but raises risk of serious adverse events
15 May, 2023 | 13:10h | UTCPhase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
In the phase 3 EPITOPE trial involving children 1 to 3 years of age with peanut allergy, epicutaneous immunotherapy by means of a peanut patch was superior to placebo in desensitizing children to peanut. https://t.co/USk6HBI9Qh#pediatrics
— NEJM (@NEJM) May 10, 2023
M-A | Timing of allergenic food introduction and risk of immunoglobulin E–mediated food allergy
11 Apr, 2023 | 14:32h | UTCNews Release: Earlier introduction of allergenic foods in children may prevent food allergies – Imperial College London
Commentary: Allergenic Food Introduction Led to Fewer Allergies, Higher Withdrawal Rate from Intervention – HCP Live
Related:
AAP Updated Recommendations for Dietary Interventions to Prevent Atopic Disease
Timing of introduction of allergenic solids for infants at high risk – Canadian Paediatric Society
Commentary on Twitter
In this study, earlier introduction of multiple allergenic foods was associated with a reduced risk of food allergy but with significant rates of withdrawal from the intervention. https://t.co/lZFkQIH9q7
— JAMA Pediatrics (@JAMAPediatrics) March 27, 2023
Cohort Study | Associations between fetal or infancy pet exposure and food allergies
3 Apr, 2023 | 13:26h | UTC
Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis
21 Mar, 2023 | 13:23h | UTCTwo Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Largest study to date of lebrikizumab supports its use for treatment of atopic dermatitis – George Washington University
Commentary: Lebrikizumab Effective for Adults, Teens With Atopic Dermatitis – HealthDay
Study | Public health policies should recommend introducing peanut products to infants at 4-6 months of age to prevent peanut allergy
20 Mar, 2023 | 13:33h | UTCCommentary: Expert reaction to research on giving peanut products to babies – Science Media Centre
Related study: Early Introduction of Allergenic Foods Can Prevent Food Allergies in High Risk Infants
Related Guidelines:
AAP Updated Recommendations for Dietary Interventions to Prevent Atopic Disease
Timing of introduction of allergenic solids for infants at high risk – Canadian Paediatric Society
Commentary from the author on Twitter
Latest paper from #LEAPStudy is now published in @JACIonline. We have looked at what happens if peanut products are introduced into the infant diet at different ages across the whole population. https://t.co/zpOlrNHOSihttps://t.co/xDIgYjezyS
More details below. @GoAllergy 1/12 pic.twitter.com/jY5MvdJ2AZ— Graham Roberts (@ProfGRoberts) January 12, 2023
RCT | Methylprednisolone vs. immunoglobulins equally effective in PIMS temporally associated with SARS-CoV-2
8 Feb, 2023 | 12:42h | UTC
SR | Skin care interventions in infants for preventing eczema and food allergy.
12 Dec, 2022 | 12:23h | UTCSkin care interventions in infants for preventing eczema and food allergy – Cochrane Library
Summary: Skin care interventions for preventing eczema and food allergy – Cochrane Library
Commentary on Twitter
Read our newest review on skin care interventions in infants for preventing eczema and food allergy! https://t.co/o8HtBXRVM5 pic.twitter.com/BPzsjJZvTf
— Cochrane Skin (@CochraneSkin) November 15, 2022
RCT | Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis.
20 Sep, 2022 | 13:20h | UTCCommentary: Dupilumab Eases Atopic Dermatitis in Children Younger Than 6 Years – HealthDay
Systematic Review | Anti‐IL‐5 therapies for asthma.
14 Jul, 2022 | 12:40h | UTCAnti‐IL‐5 therapies for asthma – Cochrane Library
Review: Management of moderate-severe atopic dermatitis in pediatric age.
27 Jun, 2022 | 11:32h | UTC
EULAR/ACR points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases.
24 Jun, 2022 | 11:23h | UTC
RCT: Effectiveness and safety of lotion, cream, gel, and ointment emollients for childhood eczema.
15 Jun, 2022 | 11:20h | UTCNews Release: The right moisturiser for children with eczema is the one that they like to use, study finds – University of Nottingham
Commentary: Lotion, Cream, Gel, and Ointment Similarly Effective for Childhood Eczema – HealthDay
Commentary on Twitter
New: @bee_study led by @riddmj found no difference in effectiveness between the four main types of emollients —lotions, creams, gels, and ointments—for childhood #eczema
The right #moisturizer is the one that children will use. https://t.co/45N5A136Kx
— The Lancet Child & Adolescent Health (@LancetChildAdol) May 24, 2022
M-A: Reproducibility of food challenge to cow’s milk.
15 Jun, 2022 | 10:42h | UTC
Position Paper: Diagnostic therapeutic care pathway for pediatric food allergies and intolerances.
14 Jun, 2022 | 11:05h | UTC
Another study suggests the Omicron variant is associated with a reduced risk of Multisystem Inflammatory Syndrome in Children compared to previous SARS-CoV-2 variants.
10 Jun, 2022 | 12:38h | UTCRelated study: Severity and Incidence of Multisystem Inflammatory Syndrome in Children During 3 SARS-CoV-2 Pandemic Waves in Israel – JAMA AND Commentary: Kids’ COVID syndrome—MIS-C—less severe in Omicron – CIDRAP
Commentary on Twitter
Study found that the risk of multisystem inflammatory syndrome in children (MIS-C) following SARS-CoV-2 infection during the #Omicron wave substantially lower compared to previous #SARSCoV2 variants. https://t.co/GYrz9XA72Z
— JAMA Pediatrics (@JAMAPediatrics) June 8, 2022
Consensus on the diagnosis and treatment of cow’s milk protein allergy.
2 Jun, 2022 | 10:56h | UTC
Cohort Study: Most egg allergy and nearly one-third of peanut allergy resolves naturally by age 6 years.
27 May, 2022 | 11:46h | UTCThe natural history of peanut and egg allergy in children up to age 6 years in the HealthNuts population-based longitudinal study – The Journal of Allergy & Clinical Immunology (link to abstract – $ for full-text)
Joint consensus guidelines on the diagnosis and management of eosinophilic esophagitis in children and adults.
25 May, 2022 | 11:32h | UTC
Guideline: Contact dermatitis.
10 May, 2022 | 10:54h | UTCGerman S1 guideline: Contact dermatitis – Journal of the German Society of Dermatology
Analysis of an intervention for emergency medical services personnel to reduce epinephrine dosing errors in infants.
19 Apr, 2022 | 01:52h | UTC
Commentary on Twitter
In this QI study, an infant resuscitation simulation intervention using 1mL syringes to draw up epinephrine (vs dosing from prefilled 10mL syringes) was associated with increased appropriate epinephrine use & fewer dosage errors, in less time. https://t.co/M3ztB1LMDi
— JAMA Network Open (@JAMANetworkOpen) April 15, 2022
Cohort Study: Predictors of severe illness in children with multisystem inflammatory syndrome after SARS-CoV-2 infection.
12 Apr, 2022 | 09:57h | UTCCommentary: Older Kids More Vulnerable to MIS-C: Study – HealthDay